Back to Search
Start Over
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
- Source :
-
British journal of haematology [Br J Haematol] 2021 Mar; Vol. 192 (6), pp. 1026-1030. Date of Electronic Publication: 2020 May 26. - Publication Year :
- 2021
-
Abstract
- Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 <superscript>mut</superscript> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR <subscript>MRD-</subscript> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR <subscript>MRD-</subscript> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1 <superscript>mut</superscript> MRD.<br /> (© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Neoplasm, Residual
Nucleophosmin
Retrospective Studies
Bridged Bicyclo Compounds, Heterocyclic administration & dosage
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics
Mutation
Neoplasm Proteins genetics
Nuclear Proteins genetics
Sulfonamides administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 192
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 32458446
- Full Text :
- https://doi.org/10.1111/bjh.16722